TABLE 3.

PB CD26+LSCs and BCR::ABL1 transcript at the time of TKI discontinuation, according to treatment. TFR: treatment-free remission.

Type of TKI before discontinuation	Imatinib	Nilotinib	Dasatinib
Patients whole cohort (n = 109)	39 (35.8%)	49 (45.0%)	21 (19.2%)
CD26+LSCs at TKI discontinuation
POSITIVE (range)	19/39 (48.7%) (0,0048–0,1184 cells/μL)	30/49 (61.2%) (0,0001–0,1039 cells/μL)	12/21 (57.1%) (0,0063–0,0695 cells/μL)
NEGATIVE	20 (51.3%)	19 (38.8%)	9 (42.9%)
BCR::ABL1 transcript at TKI discontinuation
POSITIVE (range)	19/39 (48.7%) (0,001–0,0046 copies)	26/49 (53.1%) (0,00024–0,007 copies)	10/21 (47.6%) (0,001–0,029 copies)
NEGATIVE	20/39 (51.3%)	23/49 (46.9%)	11/21 (52.4%)